405224-23-9

Basic information

• Product Name: 5-Bromo-2-chloro-3-cyanopyridine
• Synonyms: 5-Bromo-2-chloro-3-cyanopyridine;5-Bromo-2-chloronicotinonitrile;5-Bromo-2-chloropyridine-3-carbonitrile;5-Bromo-2-chloronicotinon...;3-Pyridinecarbonitrile, 5-broMo-2-chloro-;5-Bromo-2-chloropyridine-3-carbonitrile, 5-Bromo-2-chloro-3-cyanopyridine;2,5-dichloropyridine-3-carbonitrile
• CAS NO: 405224-23-9
• Molecular Formula: C₆H₂BrClN₂
• Molecular Weight: 217.45
• Product Categories: blocks;Bromides;Carboxes;Pyridines;cyanide| alkyl chloride|alkyl bromide
• Mol File: 405224-23-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 138.0 to 142.0 °C
• Boiling Point: 272.677 °C at 760 mmHg
• Flash Point: 118.711 °C
• Appearance: /Solid
• Density: 1.854 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -4.56±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 5-Bromo-2-chloro-3-cyanopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-chloro-3-cyanopyridine(405224-23-9)
• EPA Substance Registry System: 5-Bromo-2-chloro-3-cyanopyridine(405224-23-9)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25-37/38-41
• Safety Statements: 26-39
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: III
• Hazardous Substances Data: 405224-23-9(Hazardous Substances Data)

Usage

Uses

5-Bromo-2-chloro-3-cyanopyridine is used as pharmaceutical intermediate.

InChI:InChI=1/C6H2BrClN2/c7-5-1-4(2-9)6(8)10-3-5/h1,3H

Upstream product

• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 20577-27-9 2-hydroxy-3-cyanopyridine 
• 24517-64-4 2-amino-3-pyridinecarbonitrile 
• 405224-22-8 2-hydroxy-3-cyano-5-bromopyridine 
• 709652-82-4 2-amino-5-bromonicotinonitrile 
• 20577-27-9 pyrid-2-one-3-carbonitrile 
• 405224-22-8 5-bromo-2-oxo-1,2-dihydropyridine-3-carbonitrile 

Downstream Products

• 405224-24-0 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 1428799-42-1 C₂₀H₂₄BrN₅O 
• 1428799-37-4 5-bromo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine-3-amine 
• 1428798-94-0 (E)-3-(3-amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-methyl-N-((1-methyl-1H-indol-2-yl)methyl)acrylamide 
• 1428799-38-5 C₂₈H₂₈N₆O₂ 
• 1234616-31-9 ethyl 3-amino-5-bromothieno[2,3-b]pyridine-2-carboxylate 

Relevant articles and documents

Pyrazolopyridine hydroxamic acid compound as well as preparation method and application thereof

The invention relates to the technical field of chemical synthesis, in particular to a pyrazolopyridine hydroxamic acid compound as well as a preparation method and application thereof. The pyrazolopyridine hydroxamic acid compound comprises a compound as shown in a formula (1), an isomer thereof, and a hydrate thereof or a pharmaceutically acceptable salt thereof, wherein n is an integer, and R is any one of a substituted or unsubstituted aromatic ring group and a substituted alkyl group. The compound can well inhibit cancer cell proliferation, and then has an excellent treatment effect on tumors.

Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461

Abstract Two series of novel 1,5-naphthyridine and 1,6-naphthyridine derivatives were designed and synthesized based on the c-Met kinase inhibitor MK-2461 under the guidance of scaffold hopping strategy. All were tested on c-Met kinase and in vitro anti-tumor activities against Hela and A549 cell lines. The results indicated that 1,6-naphthyridine was a more promising c-Met inhibitory structure core compared with 1,5-naphthyridine. Among them, 26b and 26c showed the best enzymic and cytotoxic activities. The western blot experiments implied that the cytotoxic activity of 26c might be partially through suppressing the phosphorylation of c-Met kinase.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS

The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.